| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/28/2007 | WO2005040194A3 Methods and compositions for pdgf-c activation and inhibition |
| 06/28/2007 | WO2005035732A3 Papp-a ligands |
| 06/28/2007 | WO2005033278A8 In vivo efficacy of ny-eso-1 plus iscom |
| 06/28/2007 | WO2005028498A3 Kid3 and kid3 antibodies that bind thereto |
| 06/28/2007 | WO2004075850A3 Polyvalent immunogen |
| 06/28/2007 | WO2002083919A3 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer |
| 06/28/2007 | US20070150972 Method for detecting Nipah virus and method for providing immunoprotection against Henipa viruses |
| 06/28/2007 | US20070149769 Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs) |
| 06/28/2007 | US20070149571 Combination therapy for treating or managing acute myelocytic leukemia |
| 06/28/2007 | US20070149565 Nelfinavir conjugates and antibodies useful in immunoassay |
| 06/28/2007 | US20070149477 Stimulating a Th2 response by administering multivalent LNFPIII, an immunomodulatory glycan Lacto-N-Fucopentaose III, which contains the Lewis X trisaccharide (CD!%/antigen/); autoimmune disease; antidiabetic agents; antiarthritic agents; multiple sclerosis; colitis; psoriasis |
| 06/28/2007 | US20070149450 Method for reducing levels of c-reactive protein |
| 06/28/2007 | US20070149449 Therapeutic targets in cancer |
| 06/28/2007 | US20070148734 Hyaluronic acid mediated adenoviral transduction |
| 06/28/2007 | US20070148731 Expression control sequence cassette; a nucleotide sequence of a lac operator sequence to which a lacI repressor protein specifically binds a mutated lac; modification of the nucleotide sequence within a T5 promoter/lac operator expression control sequence provides a stable promoter/operator |
| 06/28/2007 | US20070148729 Methods for increasing neisseria protein expression and compositions thereof |
| 06/28/2007 | US20070148714 Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotherapy |
| 06/28/2007 | US20070148708 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 06/28/2007 | US20070148706 Pancreatic progenitor cells and methods for isolating the same |
| 06/28/2007 | US20070148689 Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases |
| 06/28/2007 | US20070148686 Protein present at the surface of hematopoietic stem cells of the lymphoid line and of nk cells, and uses thereof |
| 06/28/2007 | US20070148629 Composition for the preservation of viruses |
| 06/28/2007 | US20070148254 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 06/28/2007 | US20070148220 Liposomes and liposomal compositions for vaccination and drug delivery |
| 06/28/2007 | US20070148191 Use of ligands of specific antigen for the diagnosis and treatment of solid tumours and bone-related cancerous diseases |
| 06/28/2007 | US20070148190 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| 06/28/2007 | US20070148189 Stable Liquid Formulations of Botulinum Toxin |
| 06/28/2007 | US20070148188 Anthrax vaccine |
| 06/28/2007 | US20070148186 Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry |
| 06/28/2007 | US20070148185 Novel therapeutic target for protozoal diseases |
| 06/28/2007 | US20070148184 Survivin-derived peptides and use thereof |
| 06/28/2007 | US20070148183 Chemically programmable immunity |
| 06/28/2007 | US20070148182 Formulation of antigen |
| 06/28/2007 | US20070148181 Ganglioside based vaccine compositions for subcutaneous administration |
| 06/28/2007 | US20070148180 Peptide-immunoglobulin-conjugate |
| 06/28/2007 | US20070148179 Gankyrin |
| 06/28/2007 | US20070148178 Using beacizumab and antitumor agent as therapeutic treatment for mesothelioma |
| 06/28/2007 | US20070148177 Treatment with anti-vegf antibodies |
| 06/28/2007 | US20070148176 Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 06/28/2007 | US20070148175 Diagnostics and therapeutics for diseases associated with kallikrein 12 (klk12) |
| 06/28/2007 | US20070148174 Admixing with monoclonal antibodies; binds to ribonuclease; DNA or RNA maintains its intact, full-length form during production and storage |
| 06/28/2007 | US20070148173 Treatment of Acute Lung Injury, Fibrosis and Metastasis with Antagonists of Alpha V Beta 6 |
| 06/28/2007 | US20070148172 Method for the treatment of inflammatory bowel disease |
| 06/28/2007 | US20070148171 Optimized anti-CD30 antibodies |
| 06/28/2007 | US20070148170 Fc Variants With Optimized Fc Receptor Binding Properties |
| 06/28/2007 | US20070148169 Therapeutic agent for chronic arthritides diseases of childhood-related diseases |
| 06/28/2007 | US20070148168 Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions |
| 06/28/2007 | US20070148167 Non-immunostimulatory antibody and compositions containing the same |
| 06/28/2007 | US20070148166 Scfvs in photosynthetic microbes |
| 06/28/2007 | US20070148165 Recombinant antibody composition |
| 06/28/2007 | US20070148164 Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| 06/28/2007 | US20070148163 Mutants of anti-cd40 antibody |
| 06/28/2007 | US20070148162 Molecule which binds cd80 and cd86 |
| 06/28/2007 | US20070148129 Therapeutic agents and uses therefor |
| 06/28/2007 | US20070148126 comprising a fibronectin type III tenth (10Fn3) domain of 80 to 150 amino acids; Angiogenesis |
| 06/28/2007 | US20070148089 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 06/28/2007 | US20070148088 Cytotoxic therapy |
| 06/28/2007 | CA2816182A1 Pneumococcal polysaccharide conjugate vaccine |
| 06/28/2007 | CA2808919A1 Streptococcus pneumoniae capsular saccharide vaccine |
| 06/28/2007 | CA2634911A1 Neisseria meningitidis vaccines and their use |
| 06/28/2007 | CA2634898A1 Immunogenic composition |
| 06/28/2007 | CA2634377A1 Method of eliciting immune response |
| 06/28/2007 | CA2634167A1 Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
| 06/28/2007 | CA2634163A1 Compositions and methods of modulating the immune response |
| 06/28/2007 | CA2634116A1 Anti-ilt7 antibody |
| 06/28/2007 | CA2634083A1 Chimeric antibodies with part new world primate binding regions |
| 06/28/2007 | CA2634080A1 Anti-inflammatory dab |
| 06/28/2007 | CA2633793A1 Methods of clustering gene and protein sequences |
| 06/28/2007 | CA2633789A1 Conjugate vaccines |
| 06/28/2007 | CA2633772A1 Pneumococcal polysaccharide conjugate vaccine |
| 06/28/2007 | CA2633766A1 Pharmaceutical compositions comprising a bispecific single chain antibody with specificity for human cd3 and human cea and having resistance to soluble cea |
| 06/28/2007 | CA2633756A1 Pharmaceutical antibody compositions with resistance to soluble cea |
| 06/28/2007 | CA2633742A1 Composition |
| 06/28/2007 | CA2633713A1 Epha2 bite molecules and uses thereof |
| 06/28/2007 | CA2633346A1 Dna vaccine for cancer therapy |
| 06/28/2007 | CA2633331A1 Potentiation of apoptosis by monoclonal antibodies |
| 06/28/2007 | CA2633131A1 Novel cancer-associated antigen |
| 06/28/2007 | CA2633127A1 Method of producing rough strains of mycobacterium bacteria and uses thereof |
| 06/28/2007 | CA2629088A1 Intranasal vaccine for use against disease caused by enterotoxigenic escherichia coli |
| 06/27/2007 | EP1801592A1 Hepatitis C virus NS2/3 assay |
| 06/27/2007 | EP1801231A1 Method of screening baff suppressor or inhibitor |
| 06/27/2007 | EP1801219A2 Neisserial antigenic peptides |
| 06/27/2007 | EP1801218A2 Nucleic acids and proteins from streptococcus pneumoniae |
| 06/27/2007 | EP1801217A1 Group A streptococcal vaccines |
| 06/27/2007 | EP1801216A2 Bovine lactation associated immunotropic protein (CD14), encoding gene and application in B cell activation |
| 06/27/2007 | EP1801209A1 Modified human hepatitis c virus genomic rna having autonomous replicative competence |
| 06/27/2007 | EP1801208A1 Anti-a33 antibody |
| 06/27/2007 | EP1801204A1 Recombinant herpesvirus of turkeys and uses thereof |
| 06/27/2007 | EP1801124A1 Utilization of sperm membrane protein obf |
| 06/27/2007 | EP1801123A2 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 06/27/2007 | EP1801119A1 Interleukin-15 antagonist peptide |
| 06/27/2007 | EP1800697A2 Pharmaceutical compound, containing a stabilised mRNA which is optimised for translation in its coded areas |
| 06/27/2007 | EP1800693A1 Adjuvant therapy with the use of anti-glypican 3 antibody |
| 06/27/2007 | EP1800692A1 Novel adjuvant for subunit or component vaccines |
| 06/27/2007 | EP1800691A2 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 06/27/2007 | EP1800134A2 Method for diagnosing and treating crohn's disease |
| 06/27/2007 | EP1800128A2 Methods for determining and lowering caffeine concentration in fluids |
| 06/27/2007 | EP1799814A1 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof |
| 06/27/2007 | EP1799718A1 Vaccine |
| 06/27/2007 | EP1799712A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp |